Danaher Corporation $DHR Shares Purchased by Pragma Gestao DE Patrimonio Ltd.

Pragma Gestao DE Patrimonio Ltd. boosted its holdings in Danaher Corporation (NYSE:DHR) by 22.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 60,600 shares of the conglomerate’s stock after acquiring an additional 11,300 shares during the period. Danaher accounts for approximately 5.9% of Pragma Gestao DE Patrimonio Ltd.’s investment portfolio, making the stock its 6th biggest holding. Pragma Gestao DE Patrimonio Ltd.’s holdings in Danaher were worth $13,873,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG boosted its holdings in Danaher by 25.4% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock worth $83,895,000 after purchasing an additional 74,301 shares during the period. Maxi Investments CY Ltd acquired a new position in Danaher in the third quarter worth $3,251,000. Defender Capital LLC. acquired a new position in Danaher in the fourth quarter worth $35,715,000. CIBC Bancorp USA Inc. acquired a new position in Danaher in the third quarter worth $17,480,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Danaher by 303.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock worth $56,777,000 after purchasing an additional 186,584 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Stock Performance

Shares of DHR opened at $179.95 on Monday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a market cap of $127.37 billion, a price-to-earnings ratio of 34.81, a price-to-earnings-growth ratio of 2.30 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The firm has a fifty day moving average of $180.93 and a 200-day moving average of $204.62.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the company posted $1.88 earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s payout ratio is currently 30.95%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Argus reduced their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. Rothschild & Co Redburn set a $205.00 price target on shares of Danaher in a report on Friday, April 17th. Barclays reduced their price target on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $245.00 price target on shares of Danaher in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $233.61.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.